info@evinature.com www.evinature.com +1 (612) 261-0298 The CurQD® Protocol Information for prescribers & healthcare professionals The recommended dosing of CurQD® is determined based on the individual SCCAI/HBI validated activity scores filled by the patient on the Evinature website assessment page. Blood test for liver enzymes 4-8 weeks after starting QD1 is recommended. In a minority of patients, mild elevation of transaminases of up to X5 of ULN can occur, which resolve spontaneously when QD1 is continued at the same dose, or at lower doses. Rarely, QD1 may need to be discontinued because of elevated liver enzymes above X10 ULN. As this is generally unrelated to curcumin (Cura), the Cura component can usually be continued alone. Mild headaches can occur in 5-10% of patients starting QD1 and resolves usually within a few days either with continued dosing, reducing the dose for several days or with temporary 2-3 days halting and resuming CurQD®. Rare reports from Japan have noted pulmonary hypertension in patients who consumed Qing Dai long-term, for over several months of therapy. The condition was reversible in all. Our uniquely-sourced QD1 was shown safe in the clinical trial and in our clinical experience with hundreds of patients without a single case of PAH. We therefore recommend adhering to our protocol of tapering QD1 and maintenance with Cura alone. If QD1 needs to be continued due to flare of disease, an echocardiogram may be warranted after 4-6 months to monitor for PAH. As an ultimate caution, we advise against using QD1 in patients with a personal or family history of PAH, DVT, or severe cardiovascular, cerebrovascular, or liver disease. Drug interactions of curcumin are uncommon. Web-based interactions sources or our medical team can be consulted if in doubt. Drug interactions of Qing Dai have not hitherto been reported Contraindicated during pregnancy The CurQD® Protocol is a 6-week comprehensive, easy-to-follow protocol for patients with Crohn’s disease and ulcerative colitis, specifically tailored for different states of disease activity. Unlike turmeric, which is 5% curcumin, CurQD® is comprised of 95% purified gut-directed curcumin. This is combined with Qing Dai (QD, Indigo) herbal extract. Used for centuries in traditional medicine, this combination has been administered to IBD patients, in particular UC, for the past several years at Sheba Medical Center in Israel, one of the “Best 10” hospitals in the world according to Newsweek. The extract was developed by Nir Salomon, a GI-trained herbalist who heads the Integrative Medicine Unit at Sheba, currently the largest IBD referral center in the country, and Prof. Shomron Ben-Horin M.D, a renowned IBD expert who has trained in Israel and the US, is a member of IOIBD, a previous SciCom member of ECCO, and an Editorial Board member of Gut, APT and JCC. The CurQD® was licensed to Evinature by the Sheba Medical Center. Evinature is dedicated to providing only evidence-based nutraceuticals to support patients’ health, and its operations are supervised by medical professionals. Evidence Evinature’s 95% gut-directed curcumin formulation (Cura) was tested in an international multi-center randomized placebo-controlled trial and was found effective as an add-on to 5ASA in inducing remission for mild-mod UC (Lang, CGH 2015). Clinical experience with combination curcumin+QD1 (CurQD®) has shown efficacy in more severe UC and even in some biologic-refractory patients (Ben-Horin S, Case Rep Gastro 2022). In a retrospective multi-center study from Israel, CurQD® was recently reported to induce remission in over 65% of active UC patients (Kopylov, UEGW 2022). An international randomized placebo-controlled trial recently found CurQD® to be superior to placebo in inducing remission in active UC patients, including moderate-severe patients who failed biologics (Ben-Horin, CCFA, 2023), and Qing Dai (QD) was also previously found effective for active UC in another placebo-controlled RCT (Naganuma, Gastroenterology 2018). Evidence for CurQD® efficacy in pediatric patients and in Crohn’s disease is also being accumulated. Guidelines In case of further questions please don’t hesitate to contact us at info@evinature.com.